专利快速检索-快速检索全球专利，免费商用专利数据库-IPRDB

1. 发明授权

US5888813A Monoclonal antibodies against human pancreatic islet cells 失效
标题翻译：针对人胰岛细胞的单克隆抗体
公开(公告)号：US5888813A
公开(公告)日：1999-03-30
申请号：US554796
申请日：1995-11-07
申请人： Josef Endl , Michael Brandt , Herbert Jungfer , Winfried Albert , Rosemarie Kientsch-Engel , Werner Scherbaum , Wiltrud Richter , Thomas Eiermann
发明人： Josef Endl , Michael Brandt , Herbert Jungfer , Winfried Albert , Rosemarie Kientsch-Engel , Werner Scherbaum , Wiltrud Richter , Thomas Eiermann
IPC分类号： C12N5/10 , C07K1/22 , C07K14/075 , C07K14/47 , C07K16/00 , C07K16/18 , C07K16/28 , C07K16/40 , C07K16/42 , C12N5/08 , C12N5/22 , C12N5/24 , C12N15/00 , C12N15/07 , C12N15/09 , C12P21/08 , C12R1/91 , G01N33/53 , G01N33/577
CPC分类号： C07K16/40 , C07K14/47 , C07K16/18 , C07K16/4241 , C07K2317/21
摘要： The invention concerns human monoclonal antibodies of the IgG isotype against human pancreatic islet cells which can be obtained by immortalizing human lymphocytes of prediabetics or diabetics, treating the culture supernatant of the immortalized cells with a conjugate of antibodies against human Fc .gamma. and a label, subsequently treating with human immunoglobulin, incubating with immobilized human pancreatic islet cells identifying an immortalized human cell culture which produces an antibody against pancreatic islet cells via determination of the label bound to the immobilized islet cells, isolating a human immortalized cell which produces this antibody, propagating this immortalized cell and isolating the monoclonal antibody produced by these cells.The invention also concerns a process for the isolation of an islet cell antigen to which such antibodies bind as well as a method for the determination of antibodies against an islet cell antigen of the pancreas.
摘要翻译：本发明涉及针对人胰岛细胞的IgG同种型的人单克隆抗体，其可以通过使老年糖尿病患者或糖尿病患者的人淋巴细胞永生化而获得，用抗Fcγ和标记的抗体缀合物处理永生化细胞的培养物上清液，随后用人免疫球蛋白处理，与固定的人胰岛细胞孵育，鉴定永生化的人细胞培养物，其通过测定与固定化胰岛细胞结合的标记产生抗胰岛细胞的抗体，分离产生该抗体的人永生化细胞，传播该抗体永生化细胞并分离由这些细胞产生的单克隆抗体。本发明还涉及用于分离这种抗体结合的胰岛细胞抗原的方法以及用于测定抗胰岛细胞抗原的抗体的方法。

2. 发明专利

AU3578802A Detection of advanced glycation endproducts in a cerebrospinal fluid sample 未知
公开(公告)号：AU3578802A
公开(公告)日：2002-07-01
申请号：AU3578802
申请日：2001-12-18
申请人： ROSEMARIE KIENTSCH ENGEL
发明人： STAHL PETER , ELTZ HERBERT VON DER
IPC分类号： G01N33/50 , C12Q1/37 , G01N33/15 , G01N33/53 , G01N33/68
摘要： Methods for measurement of at least one advanced glycation endproduct (AGE) in a cerebrospinal fluid (CSF) sample and use of these methods in the assessment of neurodegenerative disease.

3. 发明申请

US20100159491A1 H-FABP AS EARLY PREDICTOR OF MYOCARDIAL INFARCTION 失效
标题翻译： H-FABP作为心肌梗塞的早期预后因素
公开(公告)号：US20100159491A1
公开(公告)日：2010-06-24
申请号：US12623495
申请日：2009-11-23
申请人： Georg Hess , Hendrik Huedig , Rosemarie Kientsch-Engel , Dietmar Zdunek
发明人： Georg Hess , Hendrik Huedig , Rosemarie Kientsch-Engel , Dietmar Zdunek
IPC分类号： G01N33/68 , G01N33/53
CPC分类号： G01N33/6893 , G01N2800/324
摘要： The present invention relates to a method for diagnosing myocardial infarction in a subject who suffers from acute coronary syndrome and has a cardiac troponin level which is detectable but lower than the level that is considered as being indicative for a myocardial infarction. Moreover, the present invention relates to a method for identifying a subject being susceptible to cardiac intervention, wherein the subject suffers from acute coronary syndrome and has a cardiac troponin level which is detectable but lower than a level that is considered as being indicative for a myocardial infarction. The methods of the present invention are based on the determination of H-FABP and, optionally, myoglobin in a sample of the subject and comparing the amount of H-FABP and, optionally, myoglobin to reference amounts.
摘要翻译：本发明涉及一种用于诊断患有急性冠状动脉综合征并且具有可检测但低于被认为是指示心肌梗死的水平的心肌肌钙蛋白水平的受试者心肌梗塞的方法。此外，本发明涉及用于识别易受心脏干预的受试者的方法，其中所述受试者患有急性冠状动脉综合征，并且具有可检测但低于被认为是指示心肌的水平的心肌肌钙蛋白水平梗死。本发明的方法是基于H-FABP和任选地在受试者样品中的肌红蛋白的测定，并将H-FABP和任选的肌红蛋白的量与参考量进行比较。

4. 发明授权

US5863740A Interference eliminating agent for application in immunoassays 失效
标题翻译：用于免疫测定的干扰消除剂
公开(公告)号：US5863740A
公开(公告)日：1999-01-26
申请号：US700435
申请日：1996-09-05
申请人： Rosemarie Kientsch-Engel , Frederic Donie , Michael Wiedmann
发明人： Rosemarie Kientsch-Engel , Frederic Donie , Michael Wiedmann
IPC分类号： C07D495/04 , C07K14/36 , C07K14/465 , C07K17/00 , G01N33/53 , G01N33/531 , G01N33/532 , G01N33/543
CPC分类号： C07D495/04 , G01N33/5306 , Y10S435/962 , Y10S436/824 , Y10S436/825 , Y10T436/25125
摘要： The invention concerns interference-eliminating agents for avoiding unspecific interactions in immunoassays in which avidin or streptavidin or a derivative thereof are used as the interference-eliminating agents.
摘要翻译： PCT No.PCT / EP95 / 00776 Sec。 371日期：1996年9月5日 102（e）1996年9月5日PCT PCT 1995年3月3日PCT公布。公开号WO95 / 23801 日期1995年9月8日本发明涉及用于避免免疫测定中的非特异性相互作用的干扰消除剂，其中使用抗生物素蛋白或链霉抗生物素蛋白或其衍生物作为干扰消除剂。

5. 发明申请

US20100285595A1 MYOGLOBIN AS EARLY PREDICTOR OF MYOCARDIAL INFARCTION 失效
标题翻译： MYOGLOBIN作为心肌梗塞早期预后因素
公开(公告)号：US20100285595A1
公开(公告)日：2010-11-11
申请号：US12720063
申请日：2010-03-09
申请人： Georg Hess , Hendrik Huedig , Rosemarie Kientsch-Engel , Dietmar Zdunek
发明人： Georg Hess , Hendrik Huedig , Rosemarie Kientsch-Engel , Dietmar Zdunek
IPC分类号： G01N33/72
CPC分类号： G01N33/6887 , G01N2333/805 , G01N2800/324
摘要： The present invention relates to a method for diagnosing myocardial infarction in a subject who suffers from acute coronary syndrome and has a cardiac troponin level, which is detectable, but lower than the level that is considered as being indicative for a myocardial infarction. Moreover, the present invention relates to a method for identifying a subject being susceptible to cardiac intervention, wherein the subject suffers from acute coronary syndrome and has a cardiac troponin level which is detectable, but lower than a level that is considered as being indicative for a myocardial infarction. The methods of the present invention are based on the determination of myoglobin and, optionally, Heart-type fatty acid binding protein (H-FABP) in a sample of said subject and comparing the amount of myoglobin and, optionally, H-FABP to reference amounts. Also comprised by the present invention are kits or devices to carry out the methods of the present invention.
摘要翻译：本发明涉及一种用于诊断患有急性冠状动脉综合征且具有心肌肌钙蛋白水平的受试者心肌梗塞的方法，其可检测但低于被认为是指示心肌梗塞的水平。此外，本发明涉及用于识别易受心脏干预的受试者的方法，其中所述受试者患有急性冠状动脉综合征，并且具有可检测但是低于被认为是指示性的水平的心脏肌钙蛋白水平心肌梗死本发明的方法是基于在所述受试者的样品中测定肌红蛋白和任选的心脏型脂肪酸结合蛋白（H-FABP），并将肌红蛋白和任选的H-FABP的量与参考金额本发明还包括用于实施本发明方法的试剂盒或装置。

6. 发明授权

US06630350B1 Monoclonal antibodies against a human act and serine protease complex 失效
标题翻译：针对人类行为和丝氨酸蛋白酶复合物的单克隆抗体
公开(公告)号：US06630350B1
公开(公告)日：2003-10-07
申请号：US09284128
申请日：1999-09-03
申请人： Christa Hubner-Parajsz , Hartmut Schetters , Rosemarie Kientsch-Engel , Thomas Meier , Martin Kaufmann , Andreas Gallusser , Rolf Deeg
发明人： Christa Hubner-Parajsz , Hartmut Schetters , Rosemarie Kientsch-Engel , Thomas Meier , Martin Kaufmann , Andreas Gallusser , Rolf Deeg
IPC分类号： C12H1585
CPC分类号： C07K14/705 , C07K16/38 , C07K16/40 , G01N33/57434
摘要： The invention concerns monoclonal antibodies against a complex of human ACT and a serine protease, preferably against a ACT-PSA, which have essentially no cross-reactivity with free, non-complexed human ACT and with free, non-complexed PSA, as well as diagnostic test methods for detecting serine protease-ACT complexes, in particular PSA-ACT, using these monoclonal antibodies.
摘要翻译：本发明涉及针对人ACT和丝氨酸蛋白酶的复合物的抗体，优选地针对ACT-PSA，其与游离的，非络合的人ACT和游离的，非络合的PSA基本上不具有交叉反应性，以及使用这些单克隆抗体检测丝氨酸蛋白酶-ACT复合物，特别是PSA-ACT的诊断测试方法。

7. 发明申请

US20140187652A1 L-FABP BASED DIAGNOSIS OF KIDNEY INJURY AFTER AN ACUTE EVENT OR AFTER A SURGICAL INTERVENTION 审中-公开
标题翻译：急性发作后或术后干预后的L-FABP诊断KIDNEY伤害
公开(公告)号：US20140187652A1
公开(公告)日：2014-07-03
申请号：US14197169
申请日：2014-03-04
申请人： Hendrik Heudig , Rosemarie Kientsch-Engel , Sandra Rutz
发明人： Hendrik Heudig , Rosemarie Kientsch-Engel , Sandra Rutz
IPC分类号： G01N33/53
CPC分类号： G01N33/6893 , G01N33/53 , G01N2333/47 , G01N2800/347 , G01N2800/50
摘要： Systems and methods for diagnosing acute kidney injury following an acute event or surgical intervention, based on assessing the biomarker L-FABP. Also, systems and methods for predicting the risk of an individual to suffer from a kidney injury after an acute event or surgical intervention in the future.
摘要翻译：基于评估生物标志物L-FABP，在急性事件或外科手术后诊断急性肾损伤的系统和方法。另外，用于预测未来急性事件或外科手术后个体遭受肾损伤的风险的系统和方法。

8. 发明授权

US06214568B1 Monoclonal antibodies of isotype IgG which bind specifically to glutamate decarboxylase, and uses thereof 失效
标题翻译：与谷氨酸脱羧酶特异性结合的同种型IgG的单克隆抗体及其用途
公开(公告)号：US06214568B1
公开(公告)日：2001-04-10
申请号：US09124410
申请日：1998-07-29
申请人： Josef Endl , Michael Brandt , Herbert Jungfer , Winfried Albert , Rosemarie Kientsch-Engel , Werner Scherbaum , Wiltrud Richter , Thomas Eiermann
发明人： Josef Endl , Michael Brandt , Herbert Jungfer , Winfried Albert , Rosemarie Kientsch-Engel , Werner Scherbaum , Wiltrud Richter , Thomas Eiermann
IPC分类号： G01N33573
CPC分类号： C07K16/40 , C07K14/47 , C07K16/18 , C07K16/4241 , C07K2317/21
摘要： The invention concerns human monoclonal antibodies of the IgG isotype against human pancreatic islet cells which can be obtained by immortalizing human lymphocytes of prediabetics or diabetics, treating the culture supernatant of the immortalized cells with a conjugate of antibodies against human Fc &ggr; and a label, subsequently treating with human immunoglobulin, incubating with immobilized human pancreatic islet cells identifying an immortalized human cell culture which produces an antibody against pancreatic islet cells via determination of the label bound to the immobilized islet cells, isolating a human immortalized cell which produces this antibody, propagating this immortalized cell and isolating the monoclonal antibody produced by these cells. The invention also concerns a process for the isolation of an islet cell antigen to which such antibodies bind as well as a method for the determination of antibodies against an islet cell antigen of the pancreas.
摘要翻译：本发明涉及针对人胰岛细胞的IgG同种型的人单克隆抗体，其可以通过使老年糖尿病患者或糖尿病患者的人淋巴细胞永生化而获得，用抗Fcγ和标记的抗体缀合物处理永生化细胞的培养物上清液，随后用人免疫球蛋白处理，与固定的人胰岛细胞孵育，鉴定永生化的人细胞培养物，其通过测定与固定化胰岛细胞结合的标记产生抗胰岛细胞的抗体，分离产生该抗体的人永生化细胞，传播该抗体永生化细胞并分离由这些细胞产生的单克隆抗体。本发明还涉及用于分离这种抗体结合的胰岛细胞抗原的方法以及用于测定抗胰岛细胞抗原的抗体的方法。

9. 发明授权

US08062857B1 H-FABP as early predictor of myocardial infarction 失效
标题翻译： H-FABP作为心肌梗死的早期预测因子
公开(公告)号：US08062857B1
公开(公告)日：2011-11-22
申请号：US12623495
申请日：2009-11-23
申请人： Georg Hess , Hendrik Huedig , Rosemarie Kientsch-Engel , Dietmar Zdunek
发明人： Georg Hess , Hendrik Huedig , Rosemarie Kientsch-Engel , Dietmar Zdunek
IPC分类号： G01N33/53 , G01N31/00
CPC分类号： G01N33/6893 , G01N2800/324
摘要： The present invention relates to a method for diagnosing myocardial infarction in a subject who suffers from acute coronary syndrome and has a cardiac troponin level which is detectable but lower than the level that is considered as being indicative for a myocardial infarction. Moreover, the present invention relates to a method for identifying a subject being susceptible to cardiac intervention, wherein the subject suffers from acute coronary syndrome and has a cardiac troponin level which is detectable but lower than a level that is considered as being indicative for a myocardial infarction. The methods of the present invention are based on the determination of H-FABP and, optionally, myoglobin in a sample of the subject and comparing the amount of H-FABP and, optionally, myoglobin to reference amounts.
摘要翻译：本发明涉及一种用于诊断患有急性冠状动脉综合征并且具有可检测但低于被认为是指示心肌梗死的水平的心肌肌钙蛋白水平的受试者心肌梗塞的方法。此外，本发明涉及用于识别易受心脏干预的受试者的方法，其中所述受试者患有急性冠状动脉综合征，并且具有可检测但低于被认为是指示心肌的水平的心肌肌钙蛋白水平梗死。本发明的方法是基于H-FABP和任选地在受试者样品中的肌红蛋白的测定，并将H-FABP和任选的肌红蛋白的量与参考量进行比较。

10. 发明授权

US07977105B2 Myoglobin as early predictor of myocardial infarction 失效
标题翻译：肌红蛋白作为心肌梗死的早期预测因子
公开(公告)号：US07977105B2
公开(公告)日：2011-07-12
申请号：US12720063
申请日：2010-03-09
申请人： Georg Hess , Hendrik Huedig , Rosemarie Kientsch-Engel , Dietmar Zdunek
发明人： Georg Hess , Hendrik Huedig , Rosemarie Kientsch-Engel , Dietmar Zdunek
IPC分类号： G01N33/72 , G01N33/48
CPC分类号： G01N33/6887 , G01N2333/805 , G01N2800/324
摘要： Disclosed is a method for diagnosing myocardial infarction in a subject who suffers from acute coronary syndrome and has a cardiac troponin level, which is detectable, but lower than the level that is considered as being indicative for a myocardial infarction. Also disclosed is a method for identifying a subject being susceptible to cardiac intervention, wherein the subject suffers from acute coronary syndrome and has a cardiac troponin level which is detectable, but lower than a level that is considered as being indicative for a myocardial infarction. These methods are based on the determination of myoglobin and, optionally, Heart-type fatty acid binding protein (H-FABP) in a sample of the subject and comparing the amount of myoglobin and, optionally, H-FABP to reference amounts. Also disclosed are kits or devices to carry out the methods.
摘要翻译：公开了一种用于诊断患有急性冠状动脉综合征且具有心肌肌钙蛋白水平的受试者心肌梗塞的方法，其可检测但低于被认为是指示心肌梗塞的水平。还公开了用于鉴定易受心脏干预的受试者的方法，其中受试者患有急性冠状动脉综合征，并且具有可检测但低于被认为是指示心肌梗死的水平的心肌肌钙蛋白水平。这些方法基于测定受试者样品中的肌红蛋白和任选的心脏型脂肪酸结合蛋白（H-FABP），并将肌红蛋白和任选的H-FABP的量与参考量进行比较。还公开了用于执行方法的套件或装置。

你已经成功收藏专利！

检索式保存成功!

IPRDB

热门服务

关于我们

友情链接

联系方式